Search
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. … [L46287] It was fully approved by the EMA in May 2023.[L46596]
Colchicine
go.drugbank.com/drugs/DB01394ApprovedInvestigational[L47591] It has also been investigated in other inflammatory and fibrotic conditions.[A183602] … Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus."[A183611] Its use was first approved by the FDA in 1961.
Categories: Preparations With No Effect on Uric Acid MetabolismEtoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawnEtoperidone is an atypical antidepressant introduced in Europe in 1977. … It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalUnlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines [A31846]. … In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of [DB01128] or [DB08899].
Samidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational[A235623, A235638, L34359] Although antipsychotic-induced weight gain is incompletely understood, it is thought that the opioid system plays a key role in feeding and metabolism, such that opioid antagonism … Samidorphan has been shown in animal models and clinical trials to ameliorate [olanzapine]-induced weight gain and metabolic dysfunction.
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity. … Hemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX.
Norethisterone
go.drugbank.com/drugs/DB00717ApprovedInvestigational[A10367] Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency,[A188075] and is used on its own or in combination with estrogen derivatives in a variety of applications … [L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use
Synonyms: 17-hydroxy-19-nor-17-α-pregn-4-en-20-yn-3-one, 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-oneInternational brands: Primolut-NRosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. … It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).
International brands: Sheng MinCategories: Drugs Used in DiabetesTrandolapril
go.drugbank.com/drugs/DB00519ApprovedInvestigationalIt is metabolized to its biologically active diacid form, trandolaprilat, in the liver. … Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment
Categories: Agents Acting on the Renin-Angiotensin SystemTezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigational[A243764, A243769, A243774] Tezepelumab is a human monoclonal IgG2λ antibody directed against TSLP produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.